EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Selenium and Triple Negative Breast Cancer

Despoina Sidira, Angeliki Siafaka, Dimosthenis Chrysikos, Georgios Papadopoulos, Epameinondas Stratopoulos, Dimitrios Filippou

Acta Medica Academica · 2024

DOI: 10.5644/ama2006-124.450 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Medica Academica, 2024. Verfasst von Despoina Sidira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, National and Kapodistrian University of Athens, Athens, Greece. despinasidirag@gmail.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Selenium. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The deadliest, most dangerous subtype of breast cancer is triple-negative, which lacks treatment targets and accounts for 30% of all breast cancer-related deaths worldwide. TNBC is characterized by the expression of no estrogen, proges- terone, or human epidermal growth factor 2 receptors. This suggests that new treatment modalities with fewer adverse effects are required.

Objective

The aim of the present study was to investigate the therapeutic potential of selenium compounds as an adjuvant therapy for Triple Negative Breast Cancer (TNBC), either on their own or in conjunction with nutritional supplements and chemotherapy medications.

Methods

Using the keywords “selenium” and “triple negative breast cancer”, a thorough search was conducted in the PubMed database, yielding 23 articles. The following factors were taken into consideration for inclusion: studies using TNBC cell culture lines or in vivo tumors/specimens; full-text articles from the PubMed database; studies published in the English language; experiments with statistically significant results; and selenium used alone or in combination with other antioxidants or chemotherapy. This led to the evaluation of 13 articles in this review.

Results

The results show that selenium therapy increased the anti-cancer drug’s effects and produced tumor cytotoxicity, while reducing the cellular features of the cancer (hyperproliferation, growth, and metastasis).

Discussion

This study evaluated the various selenium compounds tested, the cell lines and model organisms used, the assays performed, and the cellular pathways affected.

Conclusion

Examining the possible benefits of selenium in TNBC treatment highlights the need for more studies to confirm selenium compounds as viable co-therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsSeleniumHumansFemaleAntineoplastic AgentsAntioxidantsCell Line, TumorAnimalsSelenium CompoundsCell ProliferationDietary Supplements

Stichwörter der Autor:innen

AntioxidantsOncologySeleniumTriple Negative Breast Cancer

Substanzen

SeleniumAntineoplastic AgentsAntioxidantsSelenium Compounds

Autor:innen und Institutionen

  • Medical School, National and Kapodistrian University of Athens, Athens, Greece. despinasidirag@gmail.com.
  • Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Zitieren

APA

Sidira, D., Siafaka, A., Chrysikos, D., Papadopoulos, G., Stratopoulos, E., & Filippou, D. (2024). Selenium and Triple Negative Breast Cancer. Acta Medica Academica. https://doi.org/10.5644/ama2006-124.450

Vancouver

Sidira D, Siafaka A, Chrysikos D, Papadopoulos G, Stratopoulos E, Filippou D. Selenium and Triple Negative Breast Cancer. Acta Medica Academica. 2024. doi:10.5644/ama2006-124.450

BibTeX
@article{Sidira2024,
  author = {Sidira, Despoina and Siafaka, Angeliki and Chrysikos, Dimosthenis and Papadopoulos, Georgios and Stratopoulos, Epameinondas and Filippou, Dimitrios},
  title = {Selenium and Triple Negative Breast Cancer},
  journal = {Acta Medica Academica},
  year = {2024},
  doi = {10.5644/ama2006-124.450}
}
Kostenlos starten →